Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) just unveiled an announcement.
On March 2, 2026, Zymeworks BC Inc., a subsidiary of Zymeworks Inc., sold 30% of its future royalty payments from the HER2-targeted cancer therapy Ziihera under its collaboration agreements with Jazz Pharmaceuticals and BeOne Medicines to a newly formed special purpose partnership for $250 million. The partnership simultaneously entered into a non-recourse, fixed-rate royalty-backed term loan with Royalty Pharma, also for $250 million, secured by that royalty interest and maturing no later than December 31, 2042, with repayment caps that translate to cumulative payments of roughly 1.65x to 1.925x principal, depending on timing.
Zymeworks retains 70% of Ziihera royalties and all regulatory and commercial milestone entitlements, including up to approximately $1.5 billion in potential future milestones, with full royalty rights reverting to the company once Royalty Pharma has received its agreed return. The transaction, which is non-recourse to Zymeworks outside the pledged collateral, strengthens the company’s balance sheet with non-dilutive capital intended to extend its cash runway beyond 2028, support its share repurchase program and provide firepower for strategic acquisitions, while tying Royalty Pharma’s returns to the long-term commercial performance of Ziihera in HER2-positive gastric and biliary tract cancers.
The most recent analyst rating on (ZYME) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
The score is held back mainly by weak profitability and negative operating cash flow, with additional pressure from bearish/oversold technical signals. Offsetting these, the latest earnings call was meaningfully constructive—highlighting milestone-driven revenue growth, promising clinical updates, and a multi-year cash runway—supporting a more neutral overall outcome.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global biotechnology company focused on managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics for difficult-to-treat diseases, including cancer, inflammation and autoimmune disorders. Its strategy centers on asset and royalty aggregation from products such as Ziihera (zanidatamab-hrii) and pasritamig, leveraging proprietary antibody platforms and partnerships with major biopharmaceutical companies to generate future cash flows and support innovation.
The company engineered and developed Ziihera using its Azymetric technology and has licensed regional development and commercialization rights to Jazz Pharmaceuticals and BeOne Medicines. Zymeworks is advancing a robust pipeline in antibody-drug conjugates and multispecific antibodies, aiming to build a diversified, cash-generative portfolio while maintaining a fully integrated drug development engine.
Average Trading Volume: 704,413
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.76B
For a thorough assessment of ZYME stock, go to TipRanks’ Stock Analysis page.